Acrivon Therapeutics, Inc. Common Stock - Asset Resilience Ratio
Acrivon Therapeutics, Inc. Common Stock (ACRV) has an Asset Resilience Ratio of 64.59% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Acrivon Therapeutics, Inc. Common Stock (ACRV) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how Acrivon Therapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Acrivon Therapeutics, Inc. Common Stock's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Acrivon Therapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore long-term investment intensity of Acrivon Therapeutics, Inc. Common Stock to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $93.85 Million | 64.59% |
| Total Liquid Assets | $93.85 Million | 64.59% |
Asset Resilience Insights
- Very High Liquidity: Acrivon Therapeutics, Inc. Common Stock maintains exceptional liquid asset reserves at 64.59% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Acrivon Therapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Acrivon Therapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
F:A71 |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 2.58% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Kailera Therapeutics, Inc. Common Stock
NASDAQ:KLRA |
Biotechnology | 64.92% |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX |
Biotechnology | 78.22% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
Annual Asset Resilience Ratio for Acrivon Therapeutics, Inc. Common Stock (2021–2024)
The table below shows the annual Asset Resilience Ratio data for Acrivon Therapeutics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 71.04% | $139.66 Million | $196.59 Million | +4.91pp |
| 2023-12-31 | 66.14% | $91.44 Million | $138.26 Million | +11.93pp |
| 2022-12-31 | 54.20% | $98.23 Million | $181.23 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $106.59 Million | -- |
About Acrivon Therapeutics, Inc. Common Stock
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific propri… Read more